$LGND
LIGAND PHARMACEUTICALS INC Stock $lgnd

$lgnd Overview Financials Valuation SEC Filings Company Website

2015 Q1 Form 10-Q Financial Statement

#000088616315000062 Filed on May 11, 2015

Income Statement

Concept	2015 Q1	2014 Q1
Revenue	$14.60M	$15.96M
YoY Change	-8.5%	36.97%
Cost Of Revenue	$1.074M	$2.451M
YoY Change	-56.18%	269.68%
Gross Profit	$13.53M	$13.51M
YoY Change	0.16%	22.93%
Gross Profit Margin	92.64%	84.64%
Selling, General & Admin	$5.990M	$5.070M
YoY Change	18.15%	12.67%
% of Gross Profit	44.28%	37.54%
Research & Development	$3.368M	$3.131M
YoY Change	7.57%	27.02%
% of Gross Profit	24.9%	23.18%
Depreciation & Amortization	$650.0K	$668.0K
YoY Change	-2.69%	-0.3%
% of Gross Profit	4.8%	4.95%
Operating Expenses	$3.368M	$3.131M
YoY Change	7.57%	27.02%
Operating Profit	$3.349M	$5.100M
YoY Change	-34.33%	29.7%
Interest Expense	$2.973M	$248.0K
YoY Change	1098.79%	-72.81%
% of Operating Profit	88.77%	4.86%
Other Income/Expense, Net	-$3.423M	-$2.950M
YoY Change	16.03%	15.14%
Pretax Income	-$74.00K	$2.150M
YoY Change	-103.44%	56.93%
Income Tax	$15.00K	$53.00K
% Of Pretax Income		2.47%
Net Earnings	$754.0K	$2.097M
YoY Change	-64.04%	40.27%
Net Earnings / Revenue	5.16%	13.14%
Basic Earnings Per Share	$0.04	$0.10
Diluted Earnings Per Share	$0.04	$0.10
COMMON SHARES
Basic Shares Outstanding	19.61M shares	20.60M shares
Diluted Shares Outstanding	20.63M shares	21.21M shares

Balance Sheet

Concept	2015 Q1	2014 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$177.2M	$25.30M
YoY Change	600.4%	406.0%
Cash & Equivalents	$165.8M	$12.98M
Short-Term Investments	$11.50M	$12.30M
Other Short-Term Assets	$926.0K	$841.0K
YoY Change	10.11%	-14.71%
Inventory	$2.821M	$1.949M
Prepaid Expenses	$896.0K	$521.0K
Receivables	$7.400M	$4.700M
Other Receivables	$1.000M	$1.000M
Total Short-Term Assets	$191.7M	$33.40M
YoY Change	473.94%	88.29%
LONG-TERM ASSETS
Property, Plant & Equipment	$440.0K	$690.0K
YoY Change	-36.23%	-8.97%
Goodwill	$12.24M	$12.24M
YoY Change	0.0%	0.0%
Intangibles	$50.13M	$52.51M
YoY Change	-4.53%	-5.09%
Long-Term Investments
YoY Change
Other Assets	$358.0K	$275.0K
YoY Change	30.18%	-39.02%
Total Long-Term Assets	$71.51M	$72.07M
YoY Change	-0.77%	-10.61%
TOTAL ASSETS
Total Short-Term Assets	$191.7M	$33.40M
Total Long-Term Assets	$71.51M	$72.07M
Total Assets	$263.2M	$105.5M
YoY Change	149.57%	7.23%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$7.442M	$3.675M
YoY Change	102.5%	-33.45%
Accrued Expenses	$4.263M	$5.451M
YoY Change	-21.79%	20.65%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$2.300M	$8.500M
YoY Change	-72.94%	-47.53%
Total Short-Term Liabilities	$18.16M	$21.01M
YoY Change	-13.56%	-36.38%
LONG-TERM LIABILITIES
Long-Term Debt	$198.8M	$2.300M
YoY Change	8543.48%	-78.3%
Other Long-Term Liabilities	$780.0K	$699.0K
YoY Change	11.59%	-27.64%
Total Long-Term Liabilities	$780.0K	$699.0K
YoY Change	11.59%	-27.64%
TOTAL LIABILITIES
Total Short-Term Liabilities	$18.16M	$21.01M
Total Long-Term Liabilities	$780.0K	$699.0K
Total Liabilities	$230.8M	$40.47M
YoY Change	470.37%	-40.28%
SHAREHOLDERS EQUITY
Retained Earnings	-$658.6M	-$669.2M
YoY Change	-1.6%	-1.76%
Common Stock	$20.00K	$21.00K
YoY Change	-4.76%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$35.15M	$65.00M
YoY Change
Total Liabilities & Shareholders Equity	$263.2M	$105.5M
YoY Change	149.57%	7.23%

Cashflow Statement

Concept	2015 Q1	2014 Q1
OPERATING ACTIVITIES
Net Income	$754.0K	$2.097M
YoY Change	-64.04%	40.27%
Depreciation, Depletion And Amortization	$650.0K	$668.0K
YoY Change	-2.69%	-0.3%
Cash From Operating Activities	$7.579M	$2.577M
YoY Change	194.1%	24.01%
INVESTING ACTIVITIES
Capital Expenditures	$10.00K	$6.000K
YoY Change	66.67%	-83.78%
Acquisitions	$0.00
YoY Change
Other Investing Activities	-$2.800M	-$1.000M
YoY Change	180.0%
Cash From Investing Activities	-$2.797M	-$998.0K
YoY Change	180.26%	2835.29%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$0.00
YoY Change
Debt Paid & Issued, Net	$0.00	$3.436M
YoY Change	-100.0%	-64.63%
Cash From Financing Activities	$781.0K	-$241.0K
YoY Change	-424.07%	-97.43%
NET CHANGE
Cash From Operating Activities	$7.579M	$2.577M
Cash From Investing Activities	-$2.797M	-$998.0K
Cash From Financing Activities	$781.0K	-$241.0K
Net Change In Cash	$5.563M	$1.338M
YoY Change	315.77%	-118.22%
FREE CASH FLOW
Cash From Operating Activities	$7.579M	$2.577M
Capital Expenditures	$10.00K	$6.000K
Free Cash Flow	$7.569M	$2.571M
YoY Change	194.4%	25.97%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	89578000	USD
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1800697	shares
CY2015Q1	dei	Amendment Flag AmendmentFlag	false
CY2015Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2015Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2015Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
CY2015Q1	dei	Document Period End Date DocumentPeriodEndDate	2015-03-31
CY2015Q1	dei	Document Type DocumentType	10-Q
CY2015Q1	dei	Entity Central Index Key EntityCentralIndexKey	0000886163
CY2015Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	19666748	shares
CY2015Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2015Q1	dei	Entity Registrant Name EntityRegistrantName	LIGAND PHARMACEUTICALS INC
CY2014Q4	lgnd	Capitalized Initial Public Offering Expenses CapitalizedInitialPublicOfferingExpenses	2268000	USD
CY2015Q1	lgnd	Capitalized Initial Public Offering Expenses CapitalizedInitialPublicOfferingExpenses	2408000	USD
CY2014Q4	lgnd	Cash Deposits In Excess Of Fdic Insured Amount CashDepositsInExcessOfFdicInsuredAmount	91700000	USD
CY2015Q1	lgnd	Cash Deposits In Excess Of Fdic Insured Amount CashDepositsInExcessOfFdicInsuredAmount	107300000	USD
CY2014Q4	lgnd	Co Promote Termination Liability Current CoPromoteTerminationLiabilityCurrent	322000	USD
CY2015Q1	lgnd	Co Promote Termination Liability Current CoPromoteTerminationLiabilityCurrent	88000	USD
CY2014Q4	lgnd	Co Promote Termination Payments Receivable Current CoPromoteTerminationPaymentsReceivableCurrent	322000	USD
CY2015Q1	lgnd	Co Promote Termination Payments Receivable Current CoPromoteTerminationPaymentsReceivableCurrent	88000	USD
CY2015Q1	lgnd	Co Promotion Agreement Termination Assumed Payments Made By Assignee CoPromotionAgreementTerminationAssumedPaymentsMadeByAssignee	297000	USD
CY2015Q1	lgnd	Co Promotion Agreement Termination Fair Value Adjustments CoPromotionAgreementTerminationFairValueAdjustments	63000	USD
CY2014Q4	lgnd	Co Promotion Agreement Termination Liability CoPromotionAgreementTerminationLiability	322000	USD
CY2015Q1	lgnd	Co Promotion Agreement Termination Liability CoPromotionAgreementTerminationLiability	88000	USD
CY2014Q1	lgnd	Collaborative Research And Development And Other Revenues CollaborativeResearchAndDevelopmentAndOtherRevenues	2393000	USD
CY2015Q1	lgnd	Collaborative Research And Development And Other Revenues CollaborativeResearchAndDevelopmentAndOtherRevenues	586000	USD
CY2014Q4	lgnd	Commercial License Rights CommercialLicenseRights	4568000	USD
CY2014Q4	lgnd	Liability For Contingent Value Rights LiabilityForContingentValueRights	8353000	USD
CY2015Q1	lgnd	Commercial License Rights CommercialLicenseRights	4568000	USD
CY2014Q4	lgnd	Current Portion Of Liability For Contingent Value Rights CurrentPortionOfLiabilityForContingentValueRights	6796000	USD
CY2015Q1	lgnd	Current Portion Of Liability For Contingent Value Rights CurrentPortionOfLiabilityForContingentValueRights	3692000	USD
CY2014Q4	lgnd	Deposits Liabilities Noncurrent DepositsLiabilitiesNoncurrent	411000	USD
CY2015Q1	lgnd	Deposits Liabilities Noncurrent DepositsLiabilitiesNoncurrent	430000	USD
CY2014Q3	lgnd	Exercise Priceof Convertible Bond Hedge ExercisePriceofConvertibleBondHedge	75.05
CY2015Q1	lgnd	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Fair Value Adjustment FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetFairValueAdjustment	63000	USD
CY2015Q1	lgnd	Fair Value Measurementwith Unobservable Inputs Reconciliation Recurring Basis Liability Fair Value Adjustment Co Promotion Termination FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentCoPromotionTermination	63000	USD
CY2015Q1	lgnd	Fair Value Measurementwith Unobservable Inputs Reconciliation Recurring Basis Liability Fair Value Adjustment Contingent Liabilities FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities	1159000	USD
CY2015Q1	lgnd	Lease Expiration Year Maximum LeaseExpirationYearMaximum	2019
CY2015Q1	lgnd	Lease Expiration Year Minimum LeaseExpirationYearMinimum	2015
CY2015Q1	lgnd	Liability For Contingent Value Rights LiabilityForContingentValueRights	8213000	USD
CY2014Q3	lgnd	Line Of Credit Facility Additional Payment On Borrowings Percentage LineOfCreditFacilityAdditionalPaymentOnBorrowingsPercentage	0.06
CY2014Q4	lgnd	Long Term Portion Of Lease Exit Obligations LongTermPortionOfLeaseExitObligations	934000	USD
CY2015Q1	lgnd	Long Term Portion Of Lease Exit Obligations LongTermPortionOfLeaseExitObligations	577000	USD
CY2015Q1	lgnd	Maturity Period Of Highly Liquid Securities Maximum MaturityPeriodOfHighlyLiquidSecuritiesMaximum	P3M
CY2015Q1	lgnd	Maximum Period For Accounts Receivable Outstanding To Be Considered As Past Due MaximumPeriodForAccountsReceivableOutstandingToBeConsideredAsPastDue	P90D
CY2015Q1	lgnd	Minimum Period For Accounts Receivable Outstanding To Be Considered As Past Due MinimumPeriodForAccountsReceivableOutstandingToBeConsideredAsPastDue	P30D
CY2014Q1	lgnd	Non Cash Change In Estimated Fair Value Of Contingent Value Rights NonCashChangeInEstimatedFairValueOfContingentValueRights	-1948000	USD
CY2015Q1	lgnd	Non Cash Change In Estimated Fair Value Of Contingent Value Rights NonCashChangeInEstimatedFairValueOfContingentValueRights	-3000	USD
CY2015Q1	lgnd	Non Restricted Equity And Debt Securities With Maturity Period NonRestrictedEquityAndDebtSecuritiesWithMaturityPeriod	P3M
CY2015Q1	lgnd	Number Of Drugs Included In Product Line NumberOfDrugsIncludedInProductLine	4	drug
CY2014Q1	lgnd	Operating Lease Adjustment For Accretion And Changes In Lease Assumptions OperatingLeaseAdjustmentForAccretionAndChangesInLeaseAssumptions	200000	USD
CY2015Q1	lgnd	Operating Lease Adjustment For Accretion And Changes In Lease Assumptions OperatingLeaseAdjustmentForAccretionAndChangesInLeaseAssumptions	200000	USD
CY2015Q1	lgnd	Operating Leases Future Minimum Payments Due Future Minimum Sublease Rentals Duein Rolling Year Five OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentalsDueinRollingYearFive	71000	USD
CY2015Q1	lgnd	Operating Leases Future Minimum Payments Due Future Minimum Sublease Rentals Duein Rolling Year Four OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentalsDueinRollingYearFour	277000	USD
CY2015Q1	lgnd	Operating Leases Future Minimum Payments Due Future Minimum Sublease Rentals Duein Rolling Year Three OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentalsDueinRollingYearThree	309000	USD
CY2015Q1	lgnd	Operating Leases Future Minimum Payments Due Future Minimum Sublease Rentals Duein Rolling Year Two OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentalsDueinRollingYearTwo	1315000	USD
CY2015Q1	lgnd	Operating Leases Future Minimum Payments Due Future Minimum Sublease Rentals Next Rolling Twelve Months OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentalsNextRollingTwelveMonths	3151000	USD
CY2015Q1	lgnd	Operating Leases Of Lessee Contingent Rentals Basis Spread On Variable Rate Maximum OperatingLeasesOfLesseeContingentRentalsBasisSpreadOnVariableRateMaximum	0.035
CY2015Q1	lgnd	Operating Leases Of Lessee Contingent Rentals Basis Spread On Variable Rate Minimum OperatingLeasesOfLesseeContingentRentalsBasisSpreadOnVariableRateMinimum	0.03
CY2014Q4	lgnd	Other Other Liabilities Noncurrent OtherOtherLiabilitiesNoncurrent	32000	USD
CY2015Q1	lgnd	Other Other Liabilities Noncurrent OtherOtherLiabilitiesNoncurrent	32000	USD
CY2014Q1	lgnd	Payments To Contingent Value Right Holders PaymentsToContingentValueRightHolders	1618000	USD
CY2015Q1	lgnd	Payments To Contingent Value Right Holders PaymentsToContingentValueRightHolders	3247000	USD
CY2015Q1	lgnd	Period Allowed For Return Of Products Maximum PeriodAllowedForReturnOfProductsMaximum	P90D
CY2015Q1	lgnd	Period Allowed For Return Of Products Minimum PeriodAllowedForReturnOfProductsMinimum	P30D
CY2015Q1	lgnd	Product Shelf Life ProductShelfLife	P5Y
CY2015Q1	lgnd	Sales Returns Restocking Fee Percent SalesReturnsRestockingFeePercent	0.2
CY2014Q1	lgnd	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Forfeiture Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueForfeitureRate	0.097
CY2015Q1	lgnd	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Forfeiture Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueForfeitureRate	0.085
CY2014Q4	lgnd	Short Term Portion Of Lease Exit Obligations ShortTermPortionOfLeaseExitObligations	2356000	USD
CY2015Q1	lgnd	Short Term Portion Of Lease Exit Obligations ShortTermPortionOfLeaseExitObligations	1999000	USD
CY2014Q4	lgnd	Unamortized Debt Issuance Expense Current UnamortizedDebtIssuanceExpenseCurrent	809000	USD
CY2015Q1	lgnd	Unamortized Debt Issuance Expense Current UnamortizedDebtIssuanceExpenseCurrent	822000	USD
CY2015Q1	lgnd	Variable Interest Entity Qualitativeor Quantitative Information Loss Percentage Recorded VariableInterestEntityQualitativeorQuantitativeInformationLossPercentageRecorded	1
CY2015Q1	lgnd	Working Capital WorkingCapital	173600000	USD
CY2014Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	685000	USD
CY2015Q1	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	30000	USD
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	7698000	USD
CY2015Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	7442000	USD
CY2014Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4866000	USD
CY2015Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4263000	USD
CY2014Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	459000	USD
CY2015Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	359000	USD
CY2014Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	705000	USD
CY2015Q1	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	809000	USD
CY2014Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2643000	USD
CY2015Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2641000	USD
CY2014Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	4953000	USD
CY2015Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	9334000	USD
CY2014Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	680660000	USD
CY2015Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	684355000	USD
CY2014Q3	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	11600000	USD
CY2014Q1	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	2067000	USD
CY2015Q1	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	2914000	USD
CY2014Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	USD
CY2015Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	USD
CY2014Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	0	USD
CY2015Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	2509000	USD
CY2014Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	600000	USD
CY2015Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	600000	USD
CY2014Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1000000	shares
CY2015Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4500000	shares
CY2014Q1	us-gaap	Asset Impairment Charges AssetImpairmentCharges	109000	USD
CY2015Q1	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2014Q4	us-gaap	Assets Assets	258029000	USD
CY2015Q1	us-gaap	Assets Assets	263223000	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	185158000	USD
CY2015Q1	us-gaap	Assets Current AssetsCurrent	191713000	USD
CY2014Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	4954000	USD
CY2015Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	9334000	USD
CY2014Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	3440000	USD
CY2015Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	2725000	USD
CY2014Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2015Q1	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2014Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	8394000	USD
CY2015Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	12059000	USD
CY2014Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In The Range Of Outcomes Contingent Consideration Liability Value High BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh	-1948000	USD
CY2014Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	10126000	USD
CY2015Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	5134000	USD
CY2014Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	195908000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	160203000	USD
CY2015Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In The Range Of Outcomes Contingent Consideration Liability Value High BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh	-3000	USD
CY2014Q1	us-gaap	Business Exit Costs1 BusinessExitCosts1	204000	USD
CY2015Q1	us-gaap	Business Exit Costs1 BusinessExitCosts1	223000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11639000	USD
CY2014Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12977000	USD
CY2015Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	165766000	USD
CY2014Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	1338000	USD
CY2015Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	5563000	USD
CY2014Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	125.08
CY2014Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	3264643	shares
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	33333333	shares
CY2015Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	33333333	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	19575150	shares
CY2015Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	19658357	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	19575150	shares
CY2015Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	19658357	shares
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	20000	USD
CY2015Q1	us-gaap	Common Stock Value CommonStockValue	20000	USD
CY2015Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	11000	USD
CY2014Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1002000	USD
CY2015Q1	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	198219000	USD
CY2014Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	2451000	USD
CY2015Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	1074000	USD
CY2014Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	327000	USD
CY2015Q1	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	318000	USD
CY2014Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	150000	USD
CY2015Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	67000	USD
CY2014Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	2085000	USD
CY2015Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	2085000	USD
CY2014Q4	us-gaap	Deferred Tax Liabilities Gross Current DeferredTaxLiabilitiesGrossCurrent	257000	USD
CY2015Q1	us-gaap	Deferred Tax Liabilities Gross Current DeferredTaxLiabilitiesGrossCurrent	258000	USD
CY2014Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	2792000	USD
CY2015Q1	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	2797000	USD
CY2014Q1	us-gaap	Depreciation Depreciation	100000	USD
CY2015Q1	us-gaap	Depreciation Depreciation	100000	USD
CY2014Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	668000	USD
CY2015Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	650000	USD
CY2014Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.10
CY2015Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.04
CY2014Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0.10
CY2015Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0.04
CY2014Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.10
CY2015Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.04
CY2014Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1708000	USD
CY2015Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	795000	USD
CY2015Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements	297000	USD
CY2014Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	322000	USD
CY2015Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	88000	USD
CY2015Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases	3246000	USD
CY2015Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	297000	USD
CY2014Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	11819000	USD
CY2015Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	9498000	USD
CY2015Q1	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P20Y
CY2015Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	2400000	USD
CY2015Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	2400000	USD
CY2015Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	2400000	USD
CY2015Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	2400000	USD
CY2015Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	2400000	USD
CY2014Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5072000	USD
CY2015Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5994000	USD
CY2014Q4	us-gaap	Goodwill Goodwill	12238000	USD
CY2015Q1	us-gaap	Goodwill Goodwill	12238000	USD
CY2014Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	2150000	USD
CY2015Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-74000	USD
CY2014Q1	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	2097000	USD
CY2015Q1	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-89000	USD
CY2014Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	53000	USD
CY2015Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	15000	USD
CY2014Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2015Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-4667000	USD
CY2014Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2451000	USD
CY2015Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-5211000	USD
CY2014Q1	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	-53000	USD
CY2015Q1	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	-6000	USD
CY2014Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-116000	USD
CY2015Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-83000	USD
CY2014Q1	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	100000	USD
CY2015Q1	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	14000	USD
CY2014Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	557000	USD
CY2015Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	150000	USD
CY2014Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-24000	USD
CY2015Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	291000	USD
CY2014Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-118000	USD
CY2015Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-445000	USD
CY2014Q1	us-gaap	Increase Decrease In Restricted Cash For Operating Activities IncreaseDecreaseInRestrictedCashForOperatingActivities	0	USD
CY2015Q1	us-gaap	Increase Decrease In Restricted Cash For Operating Activities IncreaseDecreaseInRestrictedCashForOperatingActivities	-661000	USD
CY2014Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	546738	shares
CY2015Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	957369	shares
CY2014Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	50723000	USD
CY2015Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	50129000	USD
CY2014Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	62961000	USD
CY2015Q1	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	62367000	USD
CY2014Q1	us-gaap	Interest Expense InterestExpense	248000	USD
CY2015Q1	us-gaap	Interest Expense InterestExpense	2973000	USD
CY2014Q1	us-gaap	Interest Paid InterestPaid	110000	USD
CY2015Q1	us-gaap	Interest Paid InterestPaid	903000	USD
CY2014Q4	us-gaap	Interest Payable Current InterestPayableCurrent	925000	USD
CY2015Q1	us-gaap	Interest Payable Current InterestPayableCurrent	1627000	USD
CY2014Q4	us-gaap	Inventory Net InventoryNet	269000	USD
CY2015Q1	us-gaap	Inventory Net InventoryNet	2821000	USD
CY2014Q1	us-gaap	Inventory Write Down InventoryWriteDown	0	USD
CY2015Q1	us-gaap	Inventory Write Down InventoryWriteDown	2402000	USD
CY2014Q1	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	200000	USD
CY2015Q1	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	200000	USD
CY2014Q4	us-gaap	Liabilities Liabilities	233621000	USD
CY2015Q1	us-gaap	Liabilities Liabilities	230828000	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	258029000	USD
CY2015Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	263223000	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	22779000	USD
CY2015Q1	us-gaap	Liabilities Current LiabilitiesCurrent	18157000	USD
CY2014Q4	us-gaap	Minority Interest MinorityInterest	-1910000	USD
CY2015Q1	us-gaap	Minority Interest MinorityInterest	-2753000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-241000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	781000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-998000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2797000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	2577000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	7579000	USD
CY2014Q1	us-gaap	Net Income Loss NetIncomeLoss	2097000	USD
CY2015Q1	us-gaap	Net Income Loss NetIncomeLoss	754000	USD
CY2014Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	0	USD
CY2015Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-843000	USD
CY2014Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2950000	USD
CY2015Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3423000	USD
CY2014Q4	us-gaap	Notes Payable NotesPayable	196242000	USD
CY2015Q1	us-gaap	Notes Payable NotesPayable	198567000	USD
CY2014Q4	us-gaap	Notes Payable Current NotesPayableCurrent	334000	USD
CY2015Q1	us-gaap	Notes Payable Current NotesPayableCurrent	348000	USD
CY2015Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2015Q1	us-gaap	Number Of Stores NumberOfStores	3	storage_location
CY2014Q1	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	10858000	USD
CY2015Q1	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	11253000	USD
CY2014Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	5100000	USD
CY2015Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	3349000	USD
CY2015Q1	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	7647000	USD
CY2015Q1	us-gaap	Operating Leases Future Minimum Payments Due Future Minimum Sublease Rentals OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals	5123000	USD
CY2015Q1	us-gaap	Operating Leases Future Minimum Payments Due In Rolling Year Five OperatingLeasesFutureMinimumPaymentsDueInRollingYearFive	187000	USD
CY2015Q1	us-gaap	Operating Leases Future Minimum Payments Due In Rolling Year Four OperatingLeasesFutureMinimumPaymentsDueInRollingYearFour	742000	USD
CY2015Q1	us-gaap	Operating Leases Future Minimum Payments Due In Rolling Year Three OperatingLeasesFutureMinimumPaymentsDueInRollingYearThree	764000	USD
CY2015Q1	us-gaap	Operating Leases Future Minimum Payments Due In Rolling Year Two OperatingLeasesFutureMinimumPaymentsDueInRollingYearTwo	1847000	USD
CY2015Q1	us-gaap	Operating Leases Future Minimum Payments Next Rolling Twelve Months OperatingLeasesFutureMinimumPaymentsNextRollingTwelveMonths	4107000	USD
CY2014Q1	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	900000	USD
CY2015Q1	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	900000	USD
CY2014Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1069000	USD
CY2015Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	673000	USD
CY2014Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1520000	USD
CY2015Q1	us-gaap	Other Assets Current OtherAssetsCurrent	926000	USD
CY2014Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	207000	USD
CY2015Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	358000	USD
CY2014Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	8222000	USD
CY2015Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	4614000	USD
CY2014Q1	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	193000	USD
CY2015Q1	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	234000	USD
CY2014Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0	USD
CY2015Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0	USD
CY2014Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	770000	USD
CY2015Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	780000	USD
CY2014Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	0	USD
CY2015Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	1000	USD
CY2014Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-754000	USD
CY2015Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-447000	USD
CY2014Q1	us-gaap	Payments For Proceeds From Productive Assets PaymentsForProceedsFromProductiveAssets	0	USD
CY2015Q1	us-gaap	Payments For Proceeds From Productive Assets PaymentsForProceedsFromProductiveAssets	-1000	USD
CY2014Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6000	USD
CY2015Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	10000	USD
CY2014Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	835000	USD
CY2015Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	896000	USD
CY2014Q1	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	626000	USD
CY2015Q1	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	459000	USD
CY2014Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3195000	USD
CY2015Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	781000	USD
CY2014Q1	us-gaap	Profit Loss ProfitLoss	2097000	USD
CY2015Q1	us-gaap	Profit Loss ProfitLoss	-89000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3129000	USD
CY2015Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3081000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	486000	USD
CY2015Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	440000	USD
CY2014Q1	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	481000	USD
CY2015Q1	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-447000	USD
CY2014Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	12634000	USD
CY2015Q1	us-gaap	Receivables Net Current ReceivablesNetCurrent	7423000	USD
CY2014Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	3436000	USD
CY2015Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
CY2014Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3131000	USD
CY2015Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3962000	USD
CY2014Q4	us-gaap	Restricted Cash And Investments Noncurrent RestrictedCashAndInvestmentsNoncurrent	1261000	USD
CY2015Q1	us-gaap	Restricted Cash And Investments Noncurrent RestrictedCashAndInvestmentsNoncurrent	600000	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-659315000	USD
CY2015Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-658561000	USD
CY2014Q1	us-gaap	Revenues Revenues	15958000	USD
CY2015Q1	us-gaap	Revenues Revenues	14602000	USD
CY2014Q1	us-gaap	Royalty Revenue RoyaltyRevenue	7850000	USD
CY2015Q1	us-gaap	Royalty Revenue RoyaltyRevenue	10287000	USD
CY2014Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	5715000	USD
CY2015Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	3729000	USD
CY2014Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2067000	USD
CY2015Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2914000	USD
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.69
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.58
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.019
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.018
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1183763	shares
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	21.39
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	243469	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	51558000	USD
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2001677	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	28.78
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y3M
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	32.36
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	89578000	USD
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	2001677	shares
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	32.36
CY2015Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	18.35
CY2015Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	56.40
CY2014Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y4M24D
CY2015Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y7M6D
CY2015Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	65956000	USD
CY2015Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y5M12D
CY2015Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y4M13D
CY2015Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y4M13D
CY2014Q4	us-gaap	Short Term Investments ShortTermInvestments	7133000	USD
CY2015Q1	us-gaap	Short Term Investments ShortTermInvestments	11459000	USD
CY2015Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	42489	shares
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	26318000	USD
CY2015Q1	us-gaap	Stockholders Equity StockholdersEquity	35148000	USD
CY2014Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	3388000	USD
CY2015Q1	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	3177000	USD
CY2014Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	8222000	USD
CY2015Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	4614000	USD
CY2014Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	21208023	shares
CY2015Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	20630788	shares
CY2014Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	20600683	shares
CY2015Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	19611881	shares
CY2014Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	20600683	shares
CY2015Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	19611881	shares
CY2014Q1	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	60602	shares
CY2015Q1	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	61538	shares
CY2015Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Concentrations of Credit Risk</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash equivalents, investments and accounts receivable.</font></div><div style="line-height:120%;text-align:left;text-indent:60px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company invests its excess cash principally in U.S. government debt securities, investment-grade corporate debt securities and certificates of deposit. The Company has established guidelines relative to diversification and maturities that maintain safety and liquidity. These guidelines are periodically reviewed and modified to take advantage of trends in yields and interest rates. The Company did not experience any significant losses on its cash equivalents, short-term investments or restricted investments for either of the periods ending </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March 31, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December 31, 2014</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;text-indent:60px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March 31, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December 31, 2014</font><font style="font-family:inherit;font-size:10pt;">, cash deposits held at financial institutions in excess of FDIC insured amounts of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$250,000</font><font style="font-family:inherit;font-size:10pt;"> were approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$107.3 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$91.7 million</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;text-align:left;text-indent:60px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable from </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three</font><font style="font-family:inherit;font-size:10pt;"> customers were </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">77%</font><font style="font-family:inherit;font-size:10pt;"> of total accounts receivable at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March 31, 2015</font><font style="font-family:inherit;font-size:10pt;">. Accounts receivable from </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">two</font><font style="font-family:inherit;font-size:10pt;"> customers was </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">64%</font><font style="font-family:inherit;font-size:10pt;"> of total accounts receivable at </font><font style="font-family:inherit;font-size:10pt;">December 31, 2014</font><font style="font-family:inherit;font-size:10pt;">.  </font></div><div style="line-height:120%;text-align:left;text-indent:60px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company currently obtains Captisol from a single supplier.  If this supplier were not able to supply the requested amounts of Captisol and the Company's existing inventory was depleted, the Company would be unable to continue to derive revenues from the sale of Captisol until it obtained an alternative source, which might take a considerable length of time. The Company maintains inventory of Captisol, which has a </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> year shelf life, at </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> geographically spread storage locations in the United States and Europe.  If a disaster were to strike any of these locations, it could lead to supply interruptions. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div>
CY2015Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States requires the use of estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses, contingent assets and liabilities, definite and indefinite lived intangible assets, goodwill, co-promote termination payments receivable and co-promote termination liabilities, uncertain tax positions, deferred revenue, lease exit liability and income tax net operating loss carryforwards during the reporting period. The Company’s critical accounting policies are those that are both most important to the Company’s financial condition and results of operations and require the most difficult, subjective or complex judgments on the part of management in their application, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. Because of the uncertainty of factors surrounding the estimates or judgments used in the preparation of the condensed consolidated financial statements, actual results may materially vary from these estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0000886163-15-000062-index-headers.html	Edgar Link	pending
0000886163-15-000062-index.html	Edgar Link	pending
0000886163-15-000062.txt	Edgar Link	pending
0000886163-15-000062-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
lgnd-20150331.xml	Edgar Link	completed
lgnd-20150331.xsd	Edgar Link	pending
lgnd-20150331_cal.xml	Edgar Link	unprocessable
lgnd-20150331_def.xml	Edgar Link	unprocessable
lgnd-20150331_lab.xml	Edgar Link	unprocessable
lgnd-20150331_pre.xml	Edgar Link	unprocessable
lgnd-3311510q.htm	Edgar Link	pending
lgnd_33115exhibit311.htm	Edgar Link	pending
lgnd_33115exhibit312.htm	Edgar Link	pending
lgnd_33115exhibit321.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LGND
LIGAND PHARMACEUTICALS INC Stock $lgnd

2015 Q1 Form 10-Q Financial Statement

#000088616315000062 Filed on May 11, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LGND LIGAND PHARMACEUTICALS INC Stock $lgnd

2015 Q1 Form 10-Q Financial Statement

#000088616315000062 Filed on May 11, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LGND
LIGAND PHARMACEUTICALS INC Stock $lgnd